Company intelligence / Profile preview

Navamedic ASA

Ownership: Private
Development stage: Commercial

Overview

Navamedic reported strong Q1 2025 results with revenues of NOK 132.0 million (9.2% increase from Q1 2024), EBITDA of NOK 12.8 million (up from NOK 8.5 million), and improved gross margin of 40.7% (compared to 38.7% in Q1 2024)[4]. The company has secured two long-term Nordic tenders for its antibiotics portfolio in 2024[4].

Therapeutic areas: Men's HealthEndocrinologyCardiovascularNeurology
Modalities: Prescription drugsConsumer health productsHospital products
Industry: Biotech

Drug pipeline

1 asset

Flexilev

Unknown

Partnerships

Orion Corp (for distribution of Flexilev)Alex Therapeutics (for development of a companion app)

Beyond the preview

Go deeper on Navamedic ASA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Navamedic ASA.

Explore the full profile